Renal magnesium wasting associated with amphotericin B therapy
- PMID: 6475987
- DOI: 10.1016/0002-9343(84)90106-2
Renal magnesium wasting associated with amphotericin B therapy
Abstract
The effect of amphotericin B on magnesium metabolism was studied in 10 patients (aged 30 to 68 years) with systemic fungal infections. Renal magnesium wasting resulting in mild to moderate hypomagnesemia was demonstrated by the second week of therapy following relatively small cumulative dosages of amphotericin B (208 +/- 40 mg). The lowest serum levels and largest fractional excretions of magnesium were observed by the fourth week of therapy after cumulative dosages of 510 +/- 118 mg. A plateauing of the renal magnesium wasting is suggested, as there were no further increases or reductions in fractional magnesium excretion and serum magnesium level, respectively, despite continued amphotericin B administration. Reversibility of the magnesium wasting is indicated by data in three of the patients approximately one year following discontinuation of amphotericin B therapy, in whom the serum magnesium level and fractional magnesium excretion had returned to pretreatment baseline values. Although the available data do not allow precise localization of this defect, increased urinary excretion of magnesium despite its reduced filtered load suggests a tubular defect in magnesium reabsorption. Therefore, routine monitoring of the serum magnesium level during treatment with amphotericin B is recommended.
Similar articles
-
Transient hypoparathyroidism due to amphotericin B-induced hypomagnesemia in a patient with beta-thalassemia.Ann Pharmacother. 2001 Sep;35(9):1042-4. doi: 10.1345/aph.10273. Ann Pharmacother. 2001. PMID: 11573853
-
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.Clin Infect Dis. 1998 Jun;26(6):1383-96. doi: 10.1086/516353. Clin Infect Dis. 1998. PMID: 9636868 Clinical Trial.
-
Amphotericin B-associated hypertension.Ann Pharmacother. 1996 Jul-Aug;30(7-8):765-7. doi: 10.1177/106002809603000711. Ann Pharmacother. 1996. PMID: 8826557
-
Current therapy of pulmonary and disseminated fungal diseases.Chest. 1983 Jun;83(6):911-7. doi: 10.1378/chest.83.6.911. Chest. 1983. PMID: 6303713 Review. No abstract available.
-
[Commonly used antifungal agents in the treatment of systemic mycoses].Rev Clin Esp. 1995 Oct;195 Suppl 3:58-65. Rev Clin Esp. 1995. PMID: 9441308 Review. Spanish. No abstract available.
Cited by
-
Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats.Antimicrob Agents Chemother. 1991 Jul;35(7):1303-8. doi: 10.1128/AAC.35.7.1303. Antimicrob Agents Chemother. 1991. PMID: 1929286 Free PMC article.
-
Physiology of a Forgotten Electrolyte-Magnesium Disorders.Adv Kidney Dis Health. 2023 Mar;30(2):148-163. doi: 10.1053/j.akdh.2022.12.001. Adv Kidney Dis Health. 2023. PMID: 36868730 Free PMC article. Review.
-
Distal convoluted tubule.Compr Physiol. 2015 Jan;5(1):45-98. doi: 10.1002/cphy.c140002. Compr Physiol. 2015. PMID: 25589264 Free PMC article. Review.
-
Treatment of systemic fungal infections: recent progress and current problems.Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):460-75. doi: 10.1007/BF01962595. Eur J Clin Microbiol Infect Dis. 1988. PMID: 2846299 Review.
-
Hypomagnesemia and hypermagnesemia.Rev Endocr Metab Disord. 2003 May;4(2):195-206. doi: 10.1023/a:1022950321817. Rev Endocr Metab Disord. 2003. PMID: 12766548 Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources